News & Updates

Show Multimedia Only

Sweetened drinks, sugar intake up incidence, mortality of proximal colon cancer

15 Jun 2022 by

Consumption of sugar and sugar-sweetened beverages (SSBs) appears to increase proximal colon cancer incidence and mortality, particularly during later stage of tumorigenesis, reports a study.

Sweetened drinks, sugar intake up incidence, mortality of proximal colon cancer

15 Jun 2022

$Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC$

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

15 Jun 2022

The fixed-dose combination of trifluridine/tipiracil may be feasible for use in the treatment of patients with refractory esophageal squamous cell carcinoma (ESCC), with the drug showing modest clinical activity in the phase II ECTAS study.

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

15 Jun 2022

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

14 Jun 2022

Drug combinations including venetoclax seem to have a positive impact on health-related quality of life (HRQoL), or at least does not worsen it, in patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, a recent study has found.

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

14 Jun 2022

Cancer patients report high acceptance of telemedicine

14 Jun 2022 by

Patients with cancer are not averse to telemedicine, reporting satisfaction with their experience, according to a Singapore study. This high acceptance is associated with facilitating conditions such as having necessary resources and perceived improved access.

Cancer patients report high acceptance of telemedicine

14 Jun 2022

Clear guidelines needed for closed-system transfer device use with cancer drugs

13 Jun 2022 by

A survey of Canadian healthcare practitioners reveals a lack of clarity on closed-system transfer device (CSTD) compatibility with oncology biologics, as well as the lack of control drug manufacturers have as a single stakeholder to protect the quality of their products and the safety of patients who use them.

Clear guidelines needed for closed-system transfer device use with cancer drugs

13 Jun 2022

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

13 Jun 2022

In patients with early esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) following endoscopic resection (ER) does not seem to reduce the incidence of developing second primary ESCC nor cancers in other organs when compared with ER alone, according to a study.

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

13 Jun 2022

Cord blood transplantation boosts survival in acute myeloid leukaemia

11 Jun 2022

A single cord blood transplantation confers improved overall survival in adult patients with acute myeloid leukaemia, a recent study has found.

Cord blood transplantation boosts survival in acute myeloid leukaemia

11 Jun 2022

$Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML$

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

10 Jun 2022

Patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (AML) and with prior exposure to tyrosine kinase inhibitors (TKIs) may benefit from gilteritinib treatment, which leads to better remission and survival outcomes than salvage chemotherapy, a recent study has found.

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

10 Jun 2022

Neurocognitive functions decline after paediatric brain tumour radiotherapy

09 Jun 2022

While children with brain tumours already suffer from impaired neurocognitive functions, radiotherapy appears to worsen these impairments, a new study has found.

Neurocognitive functions decline after paediatric brain tumour radiotherapy

09 Jun 2022

$Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma$

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

08 Jun 2022

Ixazomib-dexamethasone (ixa-dex) and pomalidomide-dexamethasone (pom-dex) achieve comparable levels of efficacy and safety in relapsed and refractory multiple myeloma (RRMM) patients who had already been exposed to prior lenalidomide-based regimens, a recent study has found.

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

08 Jun 2022

News & Updates

Showing Oncology articles

Showing

Specialty:

Sweetened drinks, sugar intake up incidence, mortality of proximal colon cancer

Sweetened drinks, sugar intake up incidence, mortality of proximal colon cancer

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Cancer patients report high acceptance of telemedicine

Cancer patients report high acceptance of telemedicine

Clear guidelines needed for closed-system transfer device use with cancer drugs

Clear guidelines needed for closed-system transfer device use with cancer drugs

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

Postresection chemoradiotherapy does not prevent second primary tumours in ESCC

Cord blood transplantation boosts survival in acute myeloid leukaemia

Cord blood transplantation boosts survival in acute myeloid leukaemia

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

Neurocognitive functions decline after paediatric brain tumour radiotherapy

Neurocognitive functions decline after paediatric brain tumour radiotherapy

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma